MSLN and cancer: The mechanism of action of anti-MSLN ADC is similar to that of other ADCs: following target-specific binding of the ADC on the cancer cell surface, the ADC can be taken into the cell and the cytotoxic drug is released, resulting in disruption of the microtubule network, inhibition of cell division and growth, and tumor cell death [42,43,44].